This company is no longer actively trading as an independent public company (delisted, acquired, or ceased operations). This profile is retained for reference.
Founded in 2019, Novamind is building a global network of infrastructure to serve the regulated psychedelics industry. With their wholly-owned subsidiaries, Cedar Psychiatry and Cedar Clinical Research, Novamind plans to provide access to safe and legal psychedelic experiences and advance research for psychedelic medicine.
In August 2020, Novamind appointed Reid Robison Chief Medical Officer (CMO). Dr. Robison is a thought leader in psychedelic medicine, widely recognized for his contributions as a clinician and researcher towards the use of psychedelic-assisted psychotherapy in psychiatry.
Novamind Stock IPO
In November 2020, Novamind and Hinterland announced the completion of a definitive amalgamation agreement. Through the deal, Novamind completed a reverse takeover transaction with Hinterland. The merged companies were named Novamind Inc.
Novamind began trading on the Canadian Securities Exchange (CSE) on January 5th, 2021 under the ticker symbol NM.
Acquisition by Numinus
On June 10, 2022, Numinus (NUMI) acquired Novamind.
Novamind News 20 articles
- Numinus provides update on acquisition integration and announces new client financing options
- Novamind Launches Group Psychedelic Treatment for Frontline Workers
- Novamind to Host Bionomics’ PREVAIL Trial for Acute Treatment of Social Anxiety Disorder
- PRO: A Deeper Dive Into The Numinus + Novamind Merger
- Numinus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and Research
- Novamind Partner to Acquire Specialized Ibogaine Group in Brazil
- Novamind to Host MindMed Phase IIb Trial for LSD and Anxiety
- Novamind to Conduct Phase II Psilocybin Trial for Major Depressive Disorder
- A Deeper Dive Into Novamind’s Q2 Financial Results
- Novamind Reports Fiscal Q2 2022 Financial Results and Operating Highlights
- Novamind Signs Definitive Agreement to Acquire Arizona-based Clinics
- Novamind Reports FY2021 Financial Results and Operating Highlights
- Novamind Divests Non-Core Retreat Investment
- Novamind Has Applied to Have its Common Shares Posted for Trading on the OTCQB in the United States
- Novamind Doubles in Size, Adds Four New Psychedelic Mental Health Clinics
- Novamind Increases Strategic Investment in Bionomics
- Novamind Expands Psychedelic Medicine Access in Utah
- Novamind Goes Public and Carves Foothold In the Psychedelic Industry With a Unique Strategy in Mind
- Novamind Appoints Dr. Reid Robison as Chief Medical Officer
- Novamind Closes the Acquisition of Cedar Psychiatry, a Leading Psychedelic Therapy Organization in the U.S.